According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
Surveyed Oncologists and Urologists Indicate that Xtandi Holds the Most Patient Share in Later Lines of Therapy, According to a New Report from BioTrends Research Group
EXTON, Pa., Sept. 25, 2013 /PRNewswire/ — BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Johnson & Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga is the patient-share leader in the first-line asymptomatic and symptomatic metastatic castrate-resistant prostate cancer (mCRPC) settings; respondents in Q1 2013 cited conventional hormone therapy and docetaxel as lead therapies in these respective settings. Surveyed oncologists in Q3 2013 reported that Medivation/Astellas Pharma’s Xtandi holds the most patient shares in the second- and third-line mCRPC settings. The findings are from the TreatmentTrends(®) Prostate Cancer (US) Q3 2013 report, in which 50 urologists and 51 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.
The report also finds that most surveyed physicians expressed a high level of satisfaction with Zytiga and Xtandi as treatment options for mCRPC. Notably, one-third of respondents also expressed high satisfaction with Algeta/Bayer HealthCare’s Xofigo. Consistent with previous waves of research, Dendreon’s Provenge and mitoxantrone are associated with the lowest levels of overall satisfaction, according to surveyed physicians.
“The market entry of multiple agents that have prolonged overall survival in pivotal Phase III studies has created an urgent need to understand the optimal sequence in which these therapies should be given,” said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. “When considering the sequence of therapies for mCRPC, the majority of surveyed physicians agreed that they would switch to an agent with a different mechanism of action upon disease progression, use novel hormonal agents before chemotherapy and delay use of chemotherapy for as long as possible.”
TreatmentTrends(®) Prostate Cancer is a syndicated report designed to provide a view of the current and future management of prostate cancer based on primary research fielded with 50 urologists and 50 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends is also covering the launch of Xtandi and Xofigo through its LaunchTrends(®) studies.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE BioTrends Research Group